Transdermal delivery of tadalafil using a novel formulation

被引:21
|
作者
Baek, Jong-Suep
Cho, Cheong-Weon [1 ,2 ]
机构
[1] Chungnam Natl Univ, Coll Pharm, 99 Daehak Ro, Daejeon 34134, South Korea
[2] Chungnam Natl Univ, Inst Drug Res & Dev, 99 Daehak Ro, Daejeon 34134, South Korea
基金
新加坡国家研究基金会;
关键词
Hydroxypropyl-beta-cyclodextrin; pharmacokinetic; solubility; tadalafil; transdermal drug delivery; HYDROXYPROPYL-BETA-CYCLODEXTRIN; OLEIC-ACID; IN-VIVO; ERECTILE DYSFUNCTION; SKIN; ENHANCEMENT; PENETRATION; MECHANISM; EFFICACY; SAFETY;
D O I
10.3109/10717544.2015.1077291
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this work was to investigate the transdermal gel loaded with tadalafil, a practically insoluble selective phosphodiesterase-5 inhibitor (PDE5) in order to improve the solubility and bioavailability. The solubility of tadalafil in mixed solution of hydroxypropyl-beta-cyclodextrin (HPCD), polyethylene glycol (PEG) 400 and tween 80 (T2 solution) was 260.8 +/- 4.3 mu g/mL and that of tadalafil in modified T2 (M-T2) solution, which tadalafil was dissolved in 20% (w/v) HPCD at first and then mixture solutions of PEG 400 and tween 80 were added, was increased to 344.9 +/- 30.6 mu g/mL. Four gel formulae were prepared, subsequently in vitro and in vivo skin permeation studies were carried out. Interestingly, tadalafil gel in M-T2 and oleic acid (OA) (F3) could promote the percutaneous absorption of tadalafil by 179.4% in vitro and increase AUC by 223% in vivo compared with tadalafil gel in the absence of M-T2 and OA (F1). Also, there was a finding that tadalafil gel in M-T2 and OA did not cause dermal irritations in an experimental animal.
引用
收藏
页码:1571 / 1577
页数:7
相关论文
共 50 条
  • [31] Formulation and evaluation of ubidecarenone transdermal delivery systems
    Jung, Sun Young
    Kang, Eun Young
    Choi, Yoon Jung
    Chun, In Koo
    Lee, Byung Koo
    Gwak, Hye Sun
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2009, 35 (09) : 1029 - 1034
  • [32] Novel Deformable Vesicle for the Transdermal Delivery of Terbinafine Hydrochloride-Formulation and Cytotoxic Evaluation
    Johl, Shaanya
    Bhattacharyya, Sayani
    INDIAN JOURNAL OF PHARMACEUTICAL EDUCATION AND RESEARCH, 2024, 58 (02) : 460 - 469
  • [33] Zelrix™: A Novel Transdermal Formulation of Sumatriptan
    Pierce, Mark
    Marbury, Thomas
    O'Neill, Carol
    Siegel, Steven
    Du, Wei
    Sebree, Terri
    HEADACHE, 2009, 49 (06): : 817 - 825
  • [34] Microemulsion Transdermal Formulation for Simultaneous Delivery of Valsartan and Nifedipine: Formulation by Design
    Jatin Sood
    Bharti Sapra
    Ashok K. Tiwary
    AAPS PharmSciTech, 2017, 18 : 1901 - 1916
  • [35] Microemulsion Transdermal Formulation for Simultaneous Delivery of Valsartan and Nifedipine: Formulation by Design
    Sood, Jatin
    Sapra, Bharti
    Tiwary, Ashok K.
    AAPS PHARMSCITECH, 2017, 18 (06): : 1901 - 1916
  • [36] Transdermal Delivery of Tadalafil. I. Effect of Vehicles on Skin Permeation
    El Maghraby, Gamal M.
    Alanazi, Fars Kaed
    Alsarra, Ibrahim A.
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2009, 35 (03) : 329 - 336
  • [37] A novel microparticulate vaccine for melanoma cancer using transdermal delivery
    Bhowmik, Tuhin
    D'Souza, Bernadette
    Shashidharamurthy, Rangaiah
    Oettinger, Carl
    Selvaraj, Periasamy
    D'Souza, Martin J.
    JOURNAL OF MICROENCAPSULATION, 2011, 28 (04) : 294 - 300
  • [38] A Mixed Micellar Formulation for the Transdermal Delivery of an Indirubin Analog
    Seo, Seol Hwa
    Kim, Eunhwan
    Joo, Yechan
    Lee, Juseung
    Oh, Kyung Taek
    Hwang, Sung-Joo
    Choi, Kang-Yell
    PHARMACEUTICS, 2020, 12 (02)
  • [39] Formulation and evaluation of cubosomes containing colchicine for transdermal delivery
    Nasr, Mohamed
    Younes, Hassan
    Abdel-Rashid, Rania S.
    DRUG DELIVERY AND TRANSLATIONAL RESEARCH, 2020, 10 (05) : 1302 - 1313
  • [40] Formulation and in vitro evaluation of pentazocine transdermal delivery system
    Furuishi, Takayuki
    Io, Takeshi
    Fukami, Toshiro
    Suzuki, Toyofumi
    Tomono, Kazuo
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2008, 31 (07) : 1439 - 1443